bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading sharply higher Friday morning after the company reported full-year 2025 results highlighting strong growth in its flagship CyPath Lung diagnostic, even as total revenue declined following a strategic shift away from lower-margin lab services. Here’s what investors need to know.
- bioAffinity Technologies stock is surging to new heights today. What’s behind BIAF gains?
CyPath Lung Revenue Surges 87% As Test Volume Jumps
The company said CyPath Lung revenue rose 87% year over year in 2025, while the number of tests performed jumped 99%. Orders from physician offices and clinics increased 67%, which bioAffinity attributed to stronger awareness, peer-to-peer physician marketing and positive real-world clinical experience with the test.
Total 2025 revenue fell to $6.2 million from $9.4 million in 2024 because bioAffinity discontinued certain unprofitable pathology services and redirected resources toward commercializing CyPath Lung. Even so, operating expenses declined 9% to $16.7 million, reflecting cost-cutting and streamlining efforts.
Net Loss Widens Amid Warrants, Sales Expansion Spending
Net loss widened to $14.9 million from $9.0 million a year earlier, driven in part by changes in the fair value of warrants, expanded sales activity and increased clinical development spending. Cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million, after the company raised about $16.9 million in 2025 financings.
Looking ahead, bioAffinity said it expects CyPath Lung unit sales to increase more than 100% in 2026 as it expands commercialization and clinical validation efforts.
bioAffinity Stock Momentum Pushes RSI Into Overbought Territory
The Relative Strength Index (RSI) for bioAffinity Technologies fluctuated mostly within the neutral 30–70 range over the past year, with occasional dips into oversold territory and several brief spikes above the overbought threshold.
On Friday, the RSI surged above 70, signaling strong momentum and suggesting the stock may be entering overbought conditions after the latest rally.
BIAF Shares Surge Friday Morning
BIAF Price Action: bioAffinity Technologies shares were up 124.30% at $2.40 at the time of publication on Friday. The stock is near its 52-week low of $0.69, according to Benzinga Pro data.
Image: Shutterstock